18F-FACBC PET/CT与PET/MRI对比多参数MRI在中高危前列腺癌患者中的前瞻性评估(FLUCIPRO试验)
26例组织学确诊前列腺癌患者接受18F-FACBC(氟昔洛韦)PET/CT和PET/MRI及mpMRI检查,以前列腺根治术病理为金标准评估12个区域。PET/CT灵敏度最高(87%)但特异度低(56%);PET/MRI与mpMRI的AUC均显著优于PET/CT(p<0.01),两者间无差异。PET/CT和PET/MRI在7例转移淋巴结患者中仅1例真阳性。
要点
- PET/CT视觉分析灵敏度87%、特异度56%,312个区域中164个(53%)含前列腺癌。
- PET/MRI与mpMRI的AUC均显著优于PET/CT(p<0.01),两者间未检出差异。
- Gleason评分>3+4肿瘤的SUVmax和VT显著高于GS 3+3和良性增生(p<0.05)。
核心结论
- 定量18F-FACBC显像与Gleason评分显著相关,但在病灶检测中未能超越MRI。
- 18F-FACBC结合MRI混合显像可能有助于靶向活检。
研究设计与样本
- 前瞻性研究,26例组织学确诊前列腺癌男性患者。
- 注射369±10 MBq 18F-FACBC(氟昔洛韦)后即刻行PET/CT,注射后55±7分钟开始PET/MRI。
- PET扫描一周内另行mpMRI检查,以前列腺根治术病理为金标准评估12个区域。
- 临床试验注册号NCT02002455。
主要发现
- 视觉分析中312个区域有164个(53%)含前列腺癌,共识别41个肿瘤灶。
- PET/CT灵敏度87%、特异度56%。
- PET/MRI与mpMRI的AUC均显著优于PET/CT(p<0.01),PET/MRI与mpMRI之间未检出差异。
- Gleason评分>3+4肿瘤的SUVmax和VT显著高于GS 3+3和良性增生(p<0.05)。
- 442枚淋巴结可评估,PET/CT和PET/MRI在7例转移淋巴结患者中仅1例真阳性。
关键数值与推荐
- 18F-FACBC注射剂量369±10 MBq,PET/MRI于注射后55±7分钟开始。
- PET/CT灵敏度87%、特异度56%。
- PET/MRI与mpMRI的AUC均显著优于PET/CT(p<0.01)。
临床怎么用
- 作者认为18F-FACBC在MRI混合显像条件下可能有助于靶向活检。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to evaluate 18F-FACBC PET/CT, PET/MRI, and multiparametric MRI (mpMRI) in detection of primary prostate cancer (PCa). METHODS: Twenty-six men with histologically confirmed PCa underwent PET/CT immediately after injection of 369 ± 10 MBq 18F-FACBC (fluciclovine) followed by PET/MRI started 55 ± 7 min from injection. Maximum standardized uptake values (SUVmax) were measured for both hybrid PET acquisitions. A separate mpMRI was acquired within a week of the PET scans. Logan plots were used to calculate volume of distribution (VT). The presence of PCa was estimated in 12 regions with radical prostatectomy findings as ground truth. For each imaging modality, area under the curve (AUC) for detection of PCa was determined to predict diagnostic performance. The clinical trial registration number is NCT02002455. RESULTS: In the visual analysis, 164/312 (53%) regions contained PCa, and 41 tumor foci were identified. PET/CT demonstrated the highest sensitivity at 87% while its specificity was low at 56%. The AUC of both PET/MRI and mpMRI significantly (p < 0.01) outperformed that of PET/CT while no differences were detected between PET/MRI and mpMRI. SUVmax and VT of Gleason score (GS) >3 + 4 tumors were significantly (p < 0.05) higher than those for GS 3 + 3 and benign hyperplasia. A total of 442 lymph nodes were evaluable for staging, and PET/CT and PET/MRI demonstrated true-positive findings in only 1/7 patients with metastatic lymph nodes. CONCLUSIONS: Quantitative 18F-FACBC imaging significantly correlated with GS but failed to outperform MRI in lesion detection. 18F-FACBC may assist in targeted biopsies in the setting of hybrid imaging with MRI.
引用
- Jambor I, Kuisma A, Kähkönen E, et al. Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). Eur J Nucl Med Mol Imaging. 2017. PMID: 29147764. doi:10.1007/s00259-017-3875-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。